by Romain Magnez | Sep 4, 2026 | News
Vaxinano is changing scale. The Lille-based biotech, which has validated its Stellar-NP platform for nasal vaccines and immunotherapies across multiple veterinary indications, is preparing a €10M equity raise. The goal now is to industrialize production, convert...
by Romain Magnez | Sep 4, 2026 | Publications
A newly published study in Pharmaceutics provides fresh insight into the immune mechanisms behind VXN-Toxo, our intranasal vaccine based on maltodextrin nanoparticles targeting Toxoplasma gondii. Building on an earlier global vaccination campaign conducted in...
by Romain Magnez | Aug 13, 2026 | News
Vaxinano is pleased to announce the signing of an exclusive licensing agreement with ECO Animal Health Group plc for Vaxinano’s late-stage sheep vaccine candidate against toxoplasmosis. Under the agreement, ECO Animal Health will complete, in collaboration with...
by Romain Magnez | Jul 4, 2026 | News
Proud to share a new testimony highlighting the impact and importance of VXN-Toxo. VXN-Toxo is an innovative inactivated intranasal vaccine against toxoplasmosis, a globally distributed parasitic disease caused by Toxoplasma gondii, and a major cause of mortality...
by Romain Magnez | Jun 16, 2026 | News
Vaxinano was proud to participate in the latest edition of the Colloque I3M, where the team shared recent advances in vaccine research. During the event, Christophe Barnier Quer and Aurane Lecouffe represented Vaxinano and presented the progress of the company’s...
